Quantum BioPharma Ltd. (NASDAQ: QNTM) is moving its lead drug candidate, Lucid-MS, into a Phase 2 clinical trial for multiple sclerosis, marking the first time the compound will be tested in patients with the disease. The announcement came during a recent appearance by co-founder and executive co-chair Anthony Durkacz on The BioMedWire Podcast, where he discussed the company’s pipeline and its commercial partnership around unbuzzd™. For investors tracking the biopharmaceutical space, the update signals progress in a program that targets myelin degradation, the underlying mechanism of MS, and underscores Quantum’s dual strategy of drug development and royalty-generating consumer products.
According to the press release, Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Durkacz said the upcoming Phase 2 trial will be the first time the drug is tested in multiple sclerosis patients. The company’s wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of this lead compound. Quantum BioPharma (NASDAQ: QNTM) is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The progression to Phase 2 represents a critical milestone for a drug that could address a significant unmet need in MS treatment.
In addition to the MS program, Durkacz highlighted the clinical results for unbuzzd™, a product designed to accelerate alcohol metabolism. Quantum invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., a company led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd as of March 31, 2026, and the agreement includes royalty payments of 7% of sales until payments to Quantum total $250 million. After that threshold is reached, the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. This royalty stream provides a potential long-term revenue source while the company continues to invest in its drug pipeline.
The dual focus on a high-risk, high-reward drug candidate and a consumer product with near-term revenue potential may appeal to investors seeking diversified exposure in the biotech sector. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. The full press release can be viewed at https://ibn.fm/ovRTM, and more information about Quantum BioPharma (NASDAQ: QNTM) is available through BioMedWire.
BioMedWire is a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. It is one of more than 75 brands within the Dynamic Brand Portfolio at IBN, delivering services that include access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
